Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics (NASDAQ: AKRO )首席科学官Timothy Rolph于2025年8月5日出售了12,500股普通股，总价值616,299美元。这些交易分两次执行，价格在49.065美元至49.494美元之间。根据 InvestingPro 数据，该股票表现出色，过去一年上涨超过122%，目前股价接近52.79美元。

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

2025年8月12日， Akero Therapeutics（AKRO）披露2笔公司内部人交易情况。董事Henderson Jane于2025年8月12日卖出3000股。 2025年8月12日 董事 Henderson Jane 2025年8月12日 卖出 3000 47.46 14.24万 2025年8月12日 董事 Henderson Jane 2025年8月12日 买入 3000 7.01 ...

市值38.4亿美元的Akero Therapeutics, Inc. (NASDAQ:AKRO)董事Jane Henderson于2025年8月12日以每股47.457美元的价格出售了3,000股普通股，总价值为142,371美元。尽管该股票在过去一周下跌了9%，但在过去一年中表现出色，回报率达94%。 同一天，Henderson还行权获得了3,000股Akero Therapeutics普通股， ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Article ‘Count’ and ‘Share’ for Akero Therapeutics based on listed parameters only. The articles listed below published by authors from Akero Therapeutics, organized by journal and article ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

The positions in the table below reflect the Akero Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...